Review Article
The Prognostic Value of Nanog Overexpression in Lung Cancer: A Meta-Analysis
Table 4
Subgroup analysis of DFS by pathological type, publication year, NOS score, and country.
| Subgroup | No. of studies | No. of patients | P value | Pooled HR (95% CI) | PHet | I2 (%) |
| Pathological type | | | | | | | Adenocarcinoma | 2 | 290 | 0.010 | 1.85 (1.16-2.96) | 0.189 | 41.9% | Squamous cell carcinoma | 1 | 48 | ≤0.001 | 3.76 (1.89-7.49) | | | Small cell carcinoma | 1 | 50 | 0.085 | 1.26 (0.97-1.64) | | | Publication year | | | | | | | 2010-2016 | 2 | 276 | 0.008 | 1.34 (1.08-1.67) | 0.402 | 0.0% | 2017 | 2 | 222 | ≤0.001 | 2.92 (2.00-4.26) | 0.585 | 0.0% | NOS score | | | | | | | ≤7 | 1 | 50 | 0.085 | 1.26 (0.97-1.64) | | | >7 | 3 | 448 | 0.001 | 2.21 (1.36-3.61) | 0.061 | 64.2% | Country | | | | | | | China | 0 | 0 | | | | | Other | 4 | 498 | 0. 006 | 1.86 (1.20-2.90) | 0.004 | 77.2% |
|
|
DFS, disease free survival; NO, number of sample size; NOS, Newcastle-Ottawa-Scale; HR, hazard ratio; CI, confidence interval.
|